Genelux Corporation (GNLX)
(Delayed Data from NSDQ)
$3.15 USD
-0.19 (-5.69%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $3.14 -0.01 (-0.32%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GNLX 3.15 -0.19(-5.69%)
Will GNLX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GNLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GNLX
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year?
GNLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Other News for GNLX
Genelux GAAP EPS of -$0.20 beats by $0.02
Genelux reports Q2 EPS (20c), consensus (22c)
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business ...
Genelux (GNLX) Receives Buy Rating from Lucid Capital | GNLX Stock News
Genelux initiated with bullish view at Lucid Capital, here's why